A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Joann Stavole
- Phone Number: 9088091343
- Email: jstavole@rvlpharma.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects 18 to 65 years of age, inclusive
- An established diagnosis per McDonald Criteria (Polman et al 2011) of MS (either RR or SP course) that manifests a documented history of spasticity for at least 6 months prior to screening
- Spasticity due to MS as shown by a TNmAS-MAL score ≥ 2
- Expanded Disability Status Scale (EDSS) score greater than or equal to (≥) 3.0 and less than or equal to (≤) 7.0
- Absence of infections, peripheral vascular disease, painful contractures, advanced arthritis, or other conditions that hinder evaluation of joint movement
- Use of a medically highly effective form of birth control (see Section 7.8) during the study and for 3 months thereafter for women of child-bearing potential (including female subjects and female partners of non-sterile male subjects)
- Willing to sign the informed consent form (ICF)
Exclusion Criteria:
- Any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity
- In the opinion of the investigator, the patient is unable to rate their level of spasticity or distinguish it from other MS symptoms
- Concomitant use of medications that would potentially interfere with the actions of the study medication or outcome variables
- Pregnancy, lactation, or planned pregnancy during the course of the study and for 3 months after the final study visit
- Current significant cognitive deficit, severe or untreated anxiety, severe or untreated depression
- Current malignancy or history of malignancy that has not been in remission for more than 5 years, except effectively treated basal cell skin carcinoma
- Any other significant disease, disorder, or significant laboratory finding which, in the opinion of the investigator, puts the subject at risk because of participation, influences the result of the study, or affects the subject's ability to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Arbaclofen Extended-Release
Extended-release oral tablet, twice daily dosing (80 mg/day)
|
Arbaclofen Extended Release Tablets
Other Names:
|
|
Placebo Comparator: Placebo
Extended-release oral tablet, twice daily dosing
|
Placebo tablets
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline to Maintenance Treatment Period for Total Numeric-Transformed Modified Ashworth Scale Most Affected Limb (TNmAS-MAL)
Time Frame: Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
The total numerical score of a limb accounts for the sum of the 3 main joint muscular group scores.
The limb with the highest score is the most affected limb.
Lower score is better.
Scale is from 0 to 5.
|
Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
|
Responder Analysis of Ashworth Scale Score (AS-MAL-R) for Maintenance Treatment Period
Time Frame: Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
Responder status (AS-MAL-R) consists of three response categorical outcomes based on the Ashworth Scale (AS).
Where the possible outcomes are: Strong Responder, Responder, or Non-Responder
|
Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline to Maintenance Treatment Period for Total Numeric-Transformed Modified Ashworth Scale Total Limbs (TNmAS-TL)
Time Frame: Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
The total numerical score of a limb accounts for the sum of the 3 main joint muscular group scores.
The total of the 4 limbs is the total limbs score.
Lower score is better.
Scale is from 0 to 5 per joint, Maximum score per limb is 15.
Maximum total limbs score is 60.
|
Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
|
Clinician's global impression of change (CGIC) for Maintenance Treatment Period
Time Frame: Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
The clinician makes a judgment about the change from baseline of illness severity, the subject's level of distress, other aspects of impairment, and the impact of the illness on functioning.
Scale of -3 to +3, higher score is better
|
Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
|
Numeric Rating Scale of Spasticity (NRS-S) for Maintenance Treatment Period
Time Frame: Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
The Numeric Rating Scale of Spasticity is a patient rated measure of the perceived severity of spasticity using a 0-10 numeric rating scale.
Lower score is better.
|
Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
|
Expanded Disability Status Scale (EDSS) for Maintenance Treatment Period
Time Frame: Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
EDSS is a method of quantifying disability in MS and monitoring changes in the level of disability over time.
Scale ranges from 0-10, in 0.5 unit increments.
Lower score is better.
|
Maintenance Treatment Period: Visit 5 (day 77), Visit 6 (day 105), and Visit 7 (day 133)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Tina deVries, PhD, RVL Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OS440-3006
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.